Exact Sciences Corporation $EXAS Shares Purchased by Integral Health Asset Management LLC

Integral Health Asset Management LLC lifted its stake in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 100.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 200,000 shares of the medical research company’s stock after buying an additional 100,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Exact Sciences were worth $10,942,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Comerica Bank raised its stake in Exact Sciences by 9.2% during the third quarter. Comerica Bank now owns 1,954 shares of the medical research company’s stock valued at $107,000 after buying an additional 164 shares in the last quarter. FORA Capital LLC bought a new position in Exact Sciences during the 3rd quarter worth approximately $501,000. Jump Financial LLC acquired a new position in shares of Exact Sciences in the 3rd quarter worth approximately $2,849,000. Marshall Wace LLP increased its holdings in shares of Exact Sciences by 32.6% in the 3rd quarter. Marshall Wace LLP now owns 569,637 shares of the medical research company’s stock valued at $31,165,000 after acquiring an additional 139,918 shares during the last quarter. Finally, Entropy Technologies LP increased its holdings in shares of Exact Sciences by 539.8% in the 3rd quarter. Entropy Technologies LP now owns 30,749 shares of the medical research company’s stock valued at $1,682,000 after acquiring an additional 25,943 shares during the last quarter. 88.82% of the stock is owned by institutional investors.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $103.57 on Friday. The stock has a market cap of $19.77 billion, a P/E ratio of -94.15, a P/E/G ratio of 2.35 and a beta of 1.41. The firm’s 50-day simple moving average is $102.83 and its 200 day simple moving average is $83.60. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $103.75. The company has a quick ratio of 2.17, a current ratio of 2.43 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. During the same quarter last year, the firm posted ($0.06) EPS. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. Equities analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on EXAS shares. Piper Sandler cut Exact Sciences from an “overweight” rating to a “hold” rating and set a $105.00 price objective on the stock. in a research note on Monday, November 24th. Wells Fargo & Company reiterated an “equal weight” rating and set a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Robert W. Baird set a $105.00 price objective on shares of Exact Sciences in a research note on Thursday, November 20th. Canaccord Genuity Group lowered Exact Sciences from a “buy” rating to a “hold” rating and upped their target price for the company from $85.00 to $105.00 in a report on Tuesday, November 25th. Finally, TD Cowen lowered Exact Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 25th. Twenty-one investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $92.13.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.